Maxim Group Reiterates “Buy” Rating for Soligenix Inc (SNGX)

Soligenix Inc (OTC:SNGX)‘s stock had its “buy” rating reissued by Maxim Group in a research note issued on Friday, May 12th, StockTargetPrices.com reports. They presently have a $35.00 target price on the stock.

Soligenix (OTC:SNGX) traded down 2.42% on Friday, hitting $2.02. 67,125 shares of the stock traded hands. The company’s 50 day moving average price is $2.49 and its 200-day moving average price is $2.60. The stock’s market cap is $11.46 million. Soligenix has a 52-week low of $1.90 and a 52-week high of $8.50.

WARNING: This story was published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.com-unik.info/2017/06/17/maxim-group-reaffirms-buy-rating-for-soligenix-inc-sngx-updated-updated-updated.html.

Soligenix Company Profile

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Stock Target Prices

What are top analysts saying about Soligenix Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Soligenix Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit